Modulation of human natural killer activity by vasoactive intestinal peptide (VIP) family. VIP, glucagon and GHRF specifically inhibit NK activity

Regulatory Peptides

Volumn 38, Issue 1, 1992, Pages 79-87

  Sirianni, Maria Caterina ^a   Annibale, Bruno ^a   Tagliaferri, Fausto ^a   Fais, Stefano ^a   De Luca, Severino ^a   Pallone, Francesco ^b   Delle Fave, Gianfranco ^a   Aiuti, F ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Human; Natural killer cell; Vasoactive intestinal peptide; VIP antagonist

Indexed keywords

GLUCAGON; GROWTH HORMONE RELEASING FACTOR; PEPTIDE HISTIDINE ISOLEUCINE; SECRETIN; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LYMPHOCYTE; NATURAL KILLER CELL; PRIORITY JOURNAL;

CELL LINE; GLUCAGON; HUMAN; KILLER CELLS, NATURAL; SECRETIN; SOMATOTROPIN-RELEASING HORMONE; SUPPORT, NON-U.S. GOV'T; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0026593184     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/0167-0115(92)90074-5     Document Type: Article

References (28)

1. Vasoactive Intestinal Polypeptide
2. Anatomical distribution of Vasoactive Intestinal Peptide binding sites in peripheral tissues investigated by in vitro autoradiography
3. Characterization of Vasoactive Intestinal Peptide Receptors in Nervous and Immune Systems
4. Interaction of Vasoactive Intestinal Peptide with mouse lymphocytes: specific binding and modulation of mitogen responses
5. Specific binding sites for Vasoctive Intestinal Peptide on nonadherent peripheral blood lymphocytes
6. Differential effects of Vasoactive Intestinal Peptide, substance P and somatostatin on immunoglobulin synthesis and proliferation by lymphocytes from Peyer's patches, mesentheric lymph nodes and spleen
7. VIP: a neurotransmitter which reduces human NK cell activity and increases Ig synthesis
8. Effects of high in vivo levels of Vasoactive Intestinal Polypeptide on function of circulating lymphocytes in humans
9. Natural killer cells: Their role in defenses against disease
10. Mechanism of activation of human natural killer cells against tumors and virus-infected cells
11. Inhibition of in vitro granulopoiesis by autologous and allogenic human NK cells
12. The effect of vasoactive intestinal peptide on human natural killer cell function
13. Effect of VIP neuropeptide on Natural Killer cell activity from peripheral blood lymphocytes of normal subjects
14. Mechanism of human cell mediated cytotoxicity: dependence of natural killing on microtubule and microfilament integrity
15. 17) VIP
16. 17) VIP
17. Mechanism of defective natural killer cell activity in patients with AIDS is associated with defective distribution of tubulin
18. Interactions of glucagon, gut glucagon, vasoactive intestinal polypeptide and secretin with liver and fat cell plasma membranes: binding of specific sites and stimulation of adenylate cyclase
19. The receptors of the VIP family peptides (VIP, secretin, GRF, PHI, PHM, GIP, glucagon and oxyntomodulin) specificities and identity peptides
20. Vasoactive Intestinal Peptide as a biochemical marker for polymorphonuclear leukocytes
21. Release of Vasoactive Intestinal Peptide in mast cells by histamine liberators
22. Vasoactive Intestinal Peptide as a modulator of lymphocyte and immune function
23. Vasoactive Intestinal Polypeptide modulation of lymphocytes adenylate cyclase
24. Vasoactive Intestinal Polypeptide: current status
25. Vasoactive Intestinal Peptide and neuropeptide modulation of the immune response
26. High affinity specific binding of vasoactive intestinal peptide to human circulating T cells, B cells and large granular lymphocytes
27. Effects of prepro-vasoactive intestinal peptide-derived peptides on the murine immune response
28. Receptors for VIP and secretin on guinea pig pancreatic acini